Clinical Trial Update: A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tucatinib given before surgery in people with HER2-positive cancers that have spread to the brain (metastatic breast cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tukysa (tucatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING